Special Issue

Advancements and Innovations in Antibody Drug Conjugates

Message from the Guest Editors

Antibody–drug conjugates (ADCs) represent a groundbreaking advancement in targeted cancer therapy, merging the specificity of monoclonal antibodies with a highly potent cytotoxic small-molecule drug. ADCs aim to improve efficacy by reducing side effects through the specific targeting of cancer cells, sparing healthy tissues. Recent innovations in ADC development have focused on optimizing antibody engineering, bispecific antibodies, combination therapies, linker stability, and the choice of payloads to enhance the therapeutic index. Improved conjugation techniques, payload delivery mechanisms, and linker chemistries are advancing the field towards greater efficacy and safety profiles. This Special Issue highlights the latest advancements and innovations in ADC technology including recent antibody-based drug delivery systems, approved ADCs, clinical development, cytotoxic payload, drug linker design, cleavable linker design, site-specific conjugation, biodistribution, pharmacokinetics, and molecular imaging.

Guest Editors

Dr. Murali Mohan Yallapu

Dr. Shivaji Edupuganti

Dr. Ebaston Thankarajan

Deadline for manuscript submissions

30 November 2025

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).